Skip to main content
DCISDevice

What this study is

This is a prospective, non-interventional (observational) cohort study conducted within the medical network of the participating investigators and institutions. Patients meeting the eligibility criteria (see below) will be eligible for participation and the investigators will obtain written informed consent. A central Institutional Review Board (IRB), WCG IRB, will approve the protocol and each participating institution.

What's being tested

  • Treatment Recommendation Surveys

    Intervention · OTHER

    Treatment Recommendation Surveys are completed by the treating physicians before and after receiving results from the DCISionRT test, which is prognostic for risk of recurrence over 10 years and predictive for benefit from radiation therapy.

  • 7-gene biosignature

    Intervention · DEVICE

    Ordering the 7-gene biosignature assay (DCISionRT) as a part of routine care for DCIS is a prerequisite (inclusion criterion) for the study. The study is not designed to determine the efficacy of the assay, rather it is designed to meausre the impact of the assay results on treatment decisions for patients with DCIS.

Study details

Official title
A Prospective Registry Study to Evaluate the Effect of the DCISionRT Test on Treatment Decisions in Patients with DCIS Following Breast Conserving Therapy
Sponsor
PreludeDx
Conditions
DCIS
Enrolling
3,000 people
Starts
2018-02-27
Est. completion
2035-12
Record
View on ClinicalTrials.gov ↗